#Japan #Tokyo #Astellas #Menopause #VEOZAH

Astellas Presents First Real-World Data on VEOZAH™ at TMS 2025

Astellas Pharma Inc., under the leadership of CEO Naoki Okamura, has announced the presentation of real-world data for VEOZAH™ (fezolinetant) at the 2025 Annual Meeting of The Menopause Society in Orlando, Florida, scheduled for October 21-25. This groundbreaking treatment is a non-hormonal option designed specifically for managing moderate to severe vasomotor symptoms (VMS) associated with menopause, such as hot flashes and night sweats.

VEOZAH stands out as a first-in-class neurokinin 3 (NK3) receptor antagonist, which has been shown to effectively reduce the severity and frequency of VMS. The focus of the presentations will be six Astellas-sponsored posters, featuring three Late Breaking Abstracts (LBA), that collectively underscore the drug’s efficacy and safety based on real-world conditions.

Key Presentation Highlights

The discussion will center around compelling findings from the ongoing Phase IV observational study, OPTION-VMS, which enrolled women aged 40-75 who experienced bothersome VMS and were prescribed non-hormonal therapy. Two specific preliminary analyses will be shared:
1. OPTION-VMS Preliminary Analysis: This analysis evaluates the shifts in VMS impact experienced by women starting non-hormonal therapy. Insights on work productivity and VMS management will be highlighted.
2. Work Productivity Outcomes: This study reviews how initiating non-hormonal treatment can affect everyday work productivity for women.

Along with these analyses, Astellas will present a Matching-Adjusted Indirect Comparison between fezolinetant and Elinzanetant specifically focusing on treatment efficacy. Additional insights from a claims database will reveal treatment patterns and healthcare resource usage before and during fezolinetant treatment.

Expansion of Clinical Knowledge

According to Karla Martins, Executive Medical Director for Global Medical Affairs at Astellas, the company is committed to not only the clinical efficacy of its products but also to broadening understanding among healthcare providers about the nuances of menopausal symptom management. She stated, “We are pleased to share comprehensive data on fezolinetant at this year's TMS meeting. These results provide further evidence of the efficacy and safety of fezolinetant as a treatment option for moderate to severe VMS due to menopause.”

The Importance of VEOZAH Data

The real-world data being presented at the meeting is crucial for healthcare providers seeking effective treatments for patients struggling with menopausal symptoms. The poster presentations will occur on Thursday, October 23, from 6:15 PM to 7:15 PM, and will also include findings from a survey involving non-Hispanic/Latino Black or African American women in the U.S., aimed at gathering insights on treatment perceptions.

OPTION-VMS Study Overview

The OPTION-VMS study (NCT06049797) is longitudinal, assessing diverse impacts, including changes in sleep quality, menopause-related quality of life, mood, and sexual health in addition to VMS bothersomeness. A total of 998 women from 50 sites across the United States have been involved, which enhances the study's reliability and applicability to everyday clinical scenarios.

The Path Forward for VEOZAH

VEOZAH continues to represent a pivotal advancement in the treatment landscape for menopausal symptoms. Astellas’s commitment to ongoing research is evident as it seeks to address significant healthcare needs in women's health. As these presentations unfold, they are expected to generate important discussions surrounding effective management strategies for menopausal symptoms and improve overall patient outcomes.

As Astellas gears up for the TMS 2025, the company’s enthusiasm for educating the medical community about VEOZAH signals a meaningful step toward better healthcare for women experiencing menopause. With the focus on real-world evidence, the field can expect this data to play a crucial role in shaping future therapeutic practices.